MedImmune And National Institutes Of Health Begin Clinical Testing Of A Live, Attenuated Intranasal Vaccine Against An H5N1 Avian Influenza Virus
submited by kickingbird at Jun, 16, 2006 16:18 PM from Medical News Today
MedImmune, Inc.(Nasdaq: MEDI) announced today that the National Institutes of Health (NIH)has begun enrolling participants in a Phase 1 study of an intranasal H5N1influenza vaccine candidate based on the company´s live, attenuated vaccinetechnology. [click link for full article]
See Also:
Latest news in those days:
- China: A human case of avian influenza A(H10N3) reported in Yunnan Province 2 days ago
- WHO: Influenza at the human-animal interface summary and assessment, 28 March 2024 4 days ago
- WOAH: United States of America - Influenza A viruses of high pathogenicity (Infection with H5N1) (non-poultry including wild birds) (2017-) - Follow up report 46 5 days ago
- U.S.: Highly Pathogenic Avian Influenza Detected in South Dakota Dairy Herd 7 days ago
- NCDHHS: Avian Flu Detected in North Carolina Dairy Herd 8 days ago
[Go Top] [Close Window]
